Third Phase in Polymer Drug Development: — Smancs as a Prototype Model Drug for Cancer Treatment —

  • Hiroshi Maeda
Conference paper


Tumor cells are essentially identical to the normal cells of the host in view of biochemical or molecular biological events and machineries thereof. However, I see a great difference between tumor and normal cells exists at the tissue level, particularly in tumor blood vessels. Therefore, it is a wise choice to develop a drug which will seek and find this unique character at the vascular level[1]. Macromolecules with biocompatible nature can be best utilized in this respect since we found that they leak out at the tumor blood vessels more selectively and remain uncleared in the tumor tissues for long time: i.e. extravasation into interstitial tumor tissue is much enhanced, but the clearance from tumor is greatly suppressed compared to the normal tissues. I coined this phenomenon as enhanced permeability and retention (EPR) effect of macromolecules and lipids in solid tumor[2–5].


Tumor Blood Vessel Macromolecular Drug Biocompatible Nature Bone Marrow Delivery Macromolecular Therapeutics 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46: 6387–6392Google Scholar
  2. 2.
    Maeda H (1991) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Delivery Review 6: 181–202CrossRefGoogle Scholar
  3. 3.
    Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principle of macromolecular drug. Crit. Rev. Ther. Drug Carrier Syst. 6: 193–210Google Scholar
  4. 4.
    Maeda H, Seymour L W, Miyamoto Y (1992) Conjugation of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 3: 351–362CrossRefGoogle Scholar
  5. 5.
    Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M (1984) Tailor-making of protein drugs by polymer-conjugation for tumor targeting: A brief reveiw on smancs. J. Protein Chem. 3: 181–193CrossRefGoogle Scholar
  6. 6.
    Maeda H, Oda T, Matsumura Y. Kimura M (1988) Improved pharmacological properties of protein-drugs by tailoring with synthetic polymers. J. Bioactive Compatible Polymers 3: 27–43CrossRefGoogle Scholar
  7. 7.
    Yamaoka T, Tabata Y, Ikada Y (1994) Accumulation of polyvinylalcohol at inflammatory site. In: Polymeric Drugs and Drug Administration. R.M. Ottenbrite (ed.) Am. Chem. Soc, pp 163–171CrossRefGoogle Scholar
  8. 8.
    Duncan R (1992) Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drug 3: 195–210CrossRefGoogle Scholar
  9. 9.
    Tsutsumi Y, Kihara T, Yamamoto S, Kubo K, Nakagawa S, Miyake M, Horisawa Y, Kanamori T, Ikegarni H, Mayumi T (1994) Chemical modification of natural human tumor necrosis factor a with polyethylene glycol increased its antitumor potency. Jpn. J. Cancer Res. 5: 9–12CrossRefGoogle Scholar
  10. 10.
    Katre NV, Knauf MJ, Laird WJ (1987) Chemical modification of recombinant interleukin 2 by polyethytlene glycol increases its potency in murine Meth A sarcoma model. Proc. Nat. Acad. Sci. 84: 1487–1491CrossRefGoogle Scholar
  11. 11.
    Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image. Cancer Res., 44: 2115–2121Google Scholar
  12. 12.
    Suzuki F, Pollard RB, Maeda H (1989) Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic acid-styrene)-conjugated neocarzinostatin. Cancer Immunol. Immunother., 30:97–104CrossRefGoogle Scholar
  13. 13.
    Oda T, Morinaga T, Maeda H (1986) Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Exp. Biol. Med. 181: 9–17Google Scholar
  14. 14.
    Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54: 2367–2374CrossRefGoogle Scholar
  15. 15.
    Kobayashi M, Maeda H, Imai K, Konno T, Sugihara S, Yamanaka H (1991) Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology 37: 288–294CrossRefGoogle Scholar
  16. 16.
    Kimura M, Konno T, Oda T, Maeda H, Miyauchi Y (1993) Intracavitary treatment of malignant ascitic carcinomatosis with oily anticancer agents in rats. Anticancer Res. 13: 1287–1292Google Scholar
  17. 17.
    Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R (1995) Influence of molecular weight on passive tumor accumulation of soluble macromolecular drug carrier. Eur. J. Cancer (May, in press)Google Scholar
  18. 18.
    Li CJ, Miyamoto Y, Kojima Y, Maeda H (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67: 975–980CrossRefGoogle Scholar
  19. 19.
    Maeda H, Miyamoto Y (1994) SMANCS approach — Oily formulations of protein drug for arterial injection and oral administration. In: Drug Absorption Enhancement. Boer (ed) Harwood Academic Pubis, pp 221–247Google Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Hiroshi Maeda
    • 1
  1. 1.Department of MicrobiologyKumamoto University School of MedicineKumamoto 860Japan

Personalised recommendations